Table 1

Demographics and clinical characteristics of COVID-19 IBD patients treated with TNF antagonists, thiopurines or the combination

Characteristic*TNF antagonist monotherapy n=410Thiopurine monotherapy
n=155
P value†Combination therapy
n=105
P value‡
Mean age, years (SD)38.5 (16.2)45.6 (16.0)<0.00141.1 (15.0)0.13
Female, n (%)194 (47.3)73 (47.1)0.8248 (45.7)0.67
Race, n (%)
 White338 (82.4)133 (85.8)0.3489 (84.8)0.57
 Asian0.00112 (8.8)<0.00120 (12.9)10 (2.4)
 Black35 (8.5)6 (3.9)0.064 (3.8)0.10
Ethnicity, n (%)
 Hispanic63 (15.4)34 (21.9)0.0523 (21.9)0.05
CD, n (%)292 (71.2)78 (50.3)<0.00166 (62.9)0.06
UC/IBD-U, n (%)118 (28.8)77 (49.7)39 (37.1)
Disease Aactivity, n (%)
 Remission258 (62.9)98 (63.3)0.8057 (54.3)0.35
 Mild69 (16.8)30 (19.4)17 (16.2)
 Moderate/Ssevere, n (%)72 (17.6)25 (16.1)27 (25.7)
 Missing/Uunknown, n (%)6 (1.5)2 (1.2)4 (3.8)
Current smoker, n (%)16 (3.9)5 (3.2)0.706 (5.7)0.41
Any comorbidity, n (%)114 (27.8)49 (31.6)0.3740 (38.1)0.04
Cardiovascular Ddisease, n (%)15 (3.7)13 (8.4)0.0211 (10.5)0.004
BMI ≥30 kg/m2, n (%)62 (15.1)23 (14.8)0.7925 (23.8)0.10
Mesalamine/sulfasalazine, n (%)43 (10.5)61 (39.4)<0.00127 (25.7)<0.001
Corticosteroid, n (%)17 (4.1)16 (10.3)0.00516 (15.2)<0.001
Severe COVID-19, n (%)9 (2.2)15 (9.7)<0.00110 (9.5)<0.001
Death from COVID-19 or related complications, n (%)3 (0.7)3 (1.9)0.363 (2.9)0.17
  • *Percentages and n from each subcategory may not add up to the exact number of total reported cases due to missing values and/or non-mutually exclusive variables.

  • †P value comparing thiopurine monotherapy with TNF antagonist monotherapy.

  • ‡P value comparing combination therapy with TNF antagonist monotherapy.

  • BMI, body mass index; CD, Crohn’s disease; IBD-U, IBD unclassified; TNF, tumour necrosis factor.;